TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Phanes Therapeutics, Inc. Enters Clinical Supply Agreement with Roche to Evaluate PT217 Combined with Anti-PD-L1 Therapy

Thursday, May 09, 2024

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company specializing in innovative oncology drug discovery and development, has recently announced a clinical supply agreement with Roche. This agreement focuses on the investigation of PT217, Phanes' first-in-class bispecific antibody targeting DLL3 and CD47, in conjunction with Roche's anti-PD-L1 therapy, atezolizumab, for patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinomas (EP-NECs).

PT217 received orphan drug designation (ODD) from the FDA in 2022 for SCLC treatment and has recently been granted Fast Track designation for treating patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression post-platinum chemotherapy with or without a checkpoint inhibitor.

Currently, Phanes is enrolling patients in a Phase I clinical trial of PT217, known as the SKYBRIDGE study (NCT05652686), which is assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of PT217 in patients with advanced or refractory cancers expressing DLL3. The next stage of Phanes' investigation involves exploring the therapeutic potential of PT217 as part of combination therapy for SCLC, LCNEC, and EP-NECs. The collaboration with Roche will assess PT217 alongside atezolizumab in these patient groups.

Phanes, expressed enthusiasm about the partnership, stating, "Phanes is thrilled to collaborate with Roche on this innovative approach to treating patients with SCLC, LCNEC, and EP-NECs. DLL3, highly expressed in these cancers, presents a critical target for treatment. We believe the complementary mechanisms of PT217 and atezolizumab hold promise in improving patient outcomes. This collaboration signifies another significant milestone for Phanes as we continue to advance innovative cancer treatments."

Roche's TECENTRIQ® is a registered trademark.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit